GNTlabs: new brand of world-class genetic laboratories in new spaces

On Thursday, 1st of June, we ceremonially cut the ribbon of the new GNTlabs by GENNET genetic laboratories.

The vision of the laboratories was presented in introductory speeches by GENNET CEO, Michal Fazekaš, together with the Head Physician of the Genetics Programme, Monika Koudová. FutureLife CEO, Francisco Lobbosco, and Managing Partner, Hartenberg Holding Jozef Janov, also wished the laboratories good luck.

Symbolically, they not only opened the door for the laboratories to cooperate with clinics in the FutureLife group, but also to realise the ambitions of GNTlabs to cooperate with healthcare providers from all over the world. With its capacity and equipment, GNTlabs is one of the largest and most modern genetic laboratories in Europe. This will make it possible to meet the demand for genetic services much faster and more efficiently, as well as to step up the level of care. 

Work on the new laboratories took more than 2 years, with two floors of the modern building in Prague 5 now housing technically advanced facilities for laboratories of molecular genetics, cytogenetics, PGT and bioinformatics. The laboratories continue the success of the past, which dates back to 1996, when MUDr. David Stejskal founded GENNET as a centre for medical genetics. Gradual development saw the laboratories increase in importance, as reflected in the volume of tests and examinations performed. 

In the first half of 2023, we said goodbye to the old GENNET premises in Letná in Prague 7, which now primarily provides outpatient care to our clients.  ‘I am very happy and thank all those who participated in the creation of the new laboratories – this is an important milestone that gives us the opportunity to effectively help not only our clients through the precise and rapid work of our laboratories, but enables us to devote ourselves to the further education of future generations of experts, geneticists and bioinformatics’, said Michal Fazekaš, CEO. 

At GNTlabs by GENNET, we will continue to focus primarily on diseases and conditions affecting fertility, leading to birth defects, as well as hereditary cancers and the genetic testing of embryos.